INmune Bio, Inc.

NASDAQ:INMB

5.72 (USD) • At close November 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q3
Revenue 000.0140.0280.0430.0460.0380.0970.0980.0160.1630.1630.01400.0040.01100077.6880000000000000
Cost of Revenue 000000000000000000000000000000000
Gross Profit 000.0140.0280.0430.0460.0380.0970.0980.0160.1630.1630.01400.0040.01100077.6880000000000000
Gross Profit Ratio 001111111111101100010000000000000
Reseach & Development Expenses 10.0677.0538.6936.0075.9854.1484.1333.415.1594.1894.3097.0686.524.4642.4911.8592.3630.9030.7930.8671.1680.2940.1020.5150.1990.2870.1040.2680.0460.0650.0580.0280.028
General & Administrative Expenses 2.2192.8122.3382.42.5862.3092.3282.3292.3822.2152.3322.1252.5152.092.0611.3612.4561.2041.2991.4661.9161.6771.8091.3651.3415.8872.7420.160.2610.10.0620.0570.027
Selling & Marketing Expenses 00.0410000000000000000000000000000000
SG&A 2.2192.8122.3382.42.5862.3092.3282.3292.3822.2152.3322.1252.5152.092.0611.3612.4561.2041.2991.4661.9161.6771.8091.3651.3415.8872.7420.160.2610.10.0620.0570.027
Other Expenses 00.119-0.008-0.029-0.035-0.09-0.113-0.191-0.282-0.45-0.425-0.641-0.437-0.101-0.0080.0050.102-00.02200.0170.0360.010000000000
Operating Expenses 12.2869.86511.0318.4078.5716.4576.4615.7397.5416.4046.6419.1939.0356.5544.5523.224.8192.1072.0922.3323.0841.971.9111.881.546.1742.8460.4280.3080.1650.0310.1350.054
Operating Income -12.286-9.865-11.017-8.379-8.528-6.411-6.423-5.642-7.443-6.388-6.478-9.03-9.021-6.554-4.548-3.209-4.819-2.107-2.092-2.332-3.084-0.428-1.911-1.88-1.54-6.174-2.846-0.428-0.308-0.165-0.119-0.085-0.054
Operating Income Ratio 00-786.929-299.25-198.326-139.37-169.026-58.165-75.949-399.25-39.742-55.399-644.3570-1,137-293.959000-0.030000000000000
Total Other Income Expenses Net 0.1930.119-0.008-0.029-0.035-0.09-0.113-0.191-0.282-0.45-0.425-0.641-0.437-0.101-0.0080.0050.102-00.0220.0140.0170.0360.010000-0000.15-0.050
Income Before Tax -12.093-9.746-11.025-8.408-8.563-6.501-6.536-5.833-7.725-6.838-6.903-9.671-9.458-6.655-4.556-3.204-4.717-2.108-2.07-2.318-3.067-0.392-1.901-1.88-1.54-6.174-2.846-0.428-0.308-0.1650.031-0.135-0.054
Income Before Tax Ratio 00-787.5-300.286-199.14-141.326-172-60.134-78.827-427.375-42.35-59.331-675.5710-1,139-293.54000-0.030000000000000
Income Tax Expense 0-9.865-11.01714.826-8.528-6.4110.1130.1910.2820.450.42521.31-9.021-6.554-4.548-3.209-4.82-2.107-2.092-2.332-3.0841.506-1.911-12,441.903-1.54-6.174-2.846-0.428-0.30800.15-0.050
Net Income -12.093-9.746-11.025-8.408-8.563-6.501-6.649-6.024-8.007-7.288-7.328-9.671-9.458-6.655-4.556-3.204-4.717-2.108-2.07-2.318-3.067-0.392-1.901-1.88-1.54-6.174-2.846-0.428-0.308-0.1650.031-0.135-0.054
Net Income Ratio 00-787.5-300.286-199.14-141.326-174.974-62.103-81.704-455.5-44.957-59.331-675.5710-1,139-293.54000-0.030000000000000
EPS -0.6-0.5-0.61-0.47-0.48-0.36-0.37-0.34-0.45-0.41-0.41-0.56-0.55-0.44-0.32-0.25-0.36-0.2-0.19-0.22-0.28-0.039-0.2-0.17-0.14-0.55-0.25-0.038-0.027-0.0280.006-0.027-0.011
EPS Diluted -0.6-0.5-0.61-0.47-0.48-0.36-0.37-0.34-0.45-0.41-0.41-0.56-0.55-0.44-0.32-0.25-0.36-0.2-0.19-0.22-0.28-0.039-0.2-0.17-0.14-0.55-0.25-0.038-0.027-0.0280.006-0.027-0.011
EBITDA -12.286-9.8650-8.408-8.528-6.411-6.423-4.676-7.443-6.388-6.4780-9.021-6.554-4.54800000-3.084-0.428-1.911-1.88-1.54-6.174-2.8460-0.30800.15-0.050
EBITDA Ratio 00-786.929-299.25-198.326-139.37-169.026-58.165-75.949-399.25-39.742-55.399-644.3570-1,137-293.959000-0.030000000000000